ストックスクリーナーアプリを入手
0.2878
3.12%
0.0087
前日終値:
$0.2791
開ける：
$0.283
24時間の取引高:
20.49M
Relative Volume:
2.68
時価総額：
$39.97M
収益：
-
当期純損益:
$-12.89M
株価収益率:
-0.1138
EPS:
-2.53
ネットキャッシュフロー:
$-11.95M
1週間 パフォーマンス:
-48.16%
1か月 パフォーマンス:
-54.83%
6か月 パフォーマンス:
-11.17%
1年 パフォーマンス:
-75.82%
1日の値動き範囲:
$0.263
$0.2985
1週間の範囲:
$0.2511
$0.513
52週間の値動き範囲:
$0.1634
$2.3099
Plus Therapeutics Inc Stock (PSTV) Company Profile
PSTV を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
PSTV
Plus Therapeutics Inc
|
0.2878 | 38.77M | 0 | -12.89M | -11.95M | -2.53 |
|
VRTX
Vertex Pharmaceuticals Inc
|
441.36 | 111.36B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
733.04 | 77.98B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
800.01 | 50.33B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
359.27 | 47.46B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
338.19 | 37.43B | 4.98B | 69.59M | 525.67M | 0.5197 |
Plus Therapeutics Inc Stock (PSTV) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-09-03 | アップグレード | D. Boral Capital | Hold → Buy |
| 2025-03-17 | 開始されました | D. Boral Capital | Buy |
| 2021-01-25 | 開始されました | Ladenburg Thalmann | Buy |
| 2020-10-16 | 開始されました | Maxim Group | Buy |
Plus Therapeutics Inc (PSTV) 最新ニュース
Plus Therapeutics completes underwritten public equity offering - TipRanks
Plus Therapeutics Signs Underwriting Agreement With Lake Street Capital Markets - TradingView — Track All Markets
Plus Therapeutics Inc enters underwriting agreement with Lake Street Capital Markets, LLCSEC filing - marketscreener.com
Plus Therapeutics IncOn Jan 13, Co Enters Underwriting Agreement With Lake Street Capital Markets, LlcSEC Filing - TradingView — Track All Markets
Should you avoid Plus Therapeutics Inc stock right nowPortfolio Profit Report & Accurate Entry and Exit Point Alerts - baoquankhu1.vn
Whale Trades: Is UONE stock suitable for long term investingJuly 2025 Earnings & Fast Moving Stock Trade Plans - baoquankhu1.vn
Analyst Downgrade: Is UDR Inc in accumulation or distribution phaseJuly 2025 Intraday Action & Accurate Entry and Exit Point Alerts - baoquankhu1.vn
Plus Therapeutics, Inc. (NASDAQ:PSTV) Given Average Rating of "Moderate Buy" by Brokerages - MarketBeat
Plus Therapeutics Announces Pricing of Upsized $15 Million Public Offering - Sahm
Plus Therapeutics prices $15 million public offering at $0.38 per unit - Investing.com Nigeria
Plus Therapeutics Spurs After-Hours Biotech Rally; Connect Biopharma And Elutia Also Advance - Nasdaq
Plus Therapeutics Secures National Coverage Agreement with Humana for CNSide® Cerebrospinal Fluid Assay for Metastatic CNS Cancer - MSN
Plus Therapeutics stock plunges after pricing $15M units offering - MSN
Penny Cancer Stock Plus Therapeutics Raises $15 Million At Discount, Stock Plunges - Benzinga
PSTV Plunges On $15 Mln Upsized Offering - Nasdaq
Plus Therapeutics (PSTV) Shares Plummet After $15M Unit Offering - GuruFocus
Plus Therapeutics (PSTV) Launches $15M Public Offering - GuruFocus
Plus Therapeutics announces pricing of upsized $15 million public offering - marketscreener.com
Dow Update: Can Plus Therapeutics Inc reach all time highs this yearQuarterly Trade Summary & AI Enhanced Execution Alerts - baoquankhu1.vn
Sell Signal: Will Plus Therapeutics Inc stock benefit from upcoming earnings reportsJuly 2025 Recap & High Yield Stock Recommendations - moha.gov.vn
Sify Technologies, Boot Barn Holdings And 3 Stocks To Watch Heading Into Monday - Benzinga
Plus Therapeutics (PSTV) May Report Negative Earnings: Know the Trend Ahead of Q1 Release - sharewise.com
How Plus Therapeutics Inc. (XMP0) stock expands through international marketsQuarterly Portfolio Review & Risk Managed Trade Strategies - ulpravda.ru
HOKA Buying Guide: Can Plus Therapeutics Inc. stock continue upward trend - ulpravda.ru
Plus Therapeutics completes FDA meeting on REYOBIQ trial strategy By Investing.com - Investing.com Nigeria
Plus Therapeutics Announces Read Out of Type B Meeting with the FDA with Goal of Accelerating Approval of REYOBIQ™ for Leptomeningeal Metastases - Sahm
Why Plus Therapeutics Inc. stock is a value investor pickStop Loss & AI Based Buy/Sell Signal Reports - ulpravda.ru
Is Plus Therapeutics Inc. stock cheap at current valuationWeekly Profit Summary & Weekly Return Optimization Plans - ulpravda.ru
Is Plus Therapeutics Inc. stock a buy in volatile markets2025 Key Lessons & Advanced Swing Trade Entry Plans - ulpravda.ru
Can Plus Therapeutics Inc. stock continue upward trendEarnings Growth Report & Daily Price Action Insights - ulpravda.ru
Plus Therapeutics stock falls after FDA meeting on REYOBIQ trial By Investing.com - Investing.com Australia
Plus Therapeutics stock falls after FDA meeting on REYOBIQ trial - Investing.com
Plus Therapeutics Stock (PSTV) Opinions on FDA Meeting for REYOBIQ™ Approval - Quiver Quantitative
PSTV: Today's Analyst Ratings Maintains 'Buy' with Consistent Pr - GuruFocus
Plus Therapeutics' (PSTV) Buy Rating Reaffirmed at D. Boral Capital - MarketBeat
Plus Therapeutics (PSTV) Advances with FDA on REYOBIQ Trial for Leptomeningeal Metastases - GuruFocus
Plus Therapeutics announces read out of Type B meeting with the FDA - MarketScreener
Plus Therapeutics completes FDA meeting on REYOBIQ trial strategy - Investing.com
Plus Therapeutics, Inc. Completes FDA Type B Meeting on REYOBIQ Pivotal Trial Strategy for Leptomeningeal Metastases - Quiver Quantitative
Plus Therapeutics Announces Read Out of Type B Meeting with - GlobeNewswire
How Plus Therapeutics Inc. stock reacts to job market dataSector Performance Drivers & Minimal Capital Trading - ulpravda.ru
2026 world cup points table rankings: How Plus Therapeutics Inc. stock responds to policy changes2026 world cup usa national team round of 32 star players set piece tactics knockout prediction tactical review - ulpravda.ru
Plus Therapeutics (PSTV) Reports Q1 Loss, Misses Revenue Estimates - MSN
Analyst Downgrade: How Plus Therapeutics Inc XMP0 stock expands through international marketsMarket Risk Summary & Accurate Intraday Trade Tips - moha.gov.vn
Guidance Update: Can Plus Therapeutics Inc XMP0 stock attract analyst upgradesJuly 2025 Setups & Safe Entry Momentum Tips - moha.gov.vn
Plus Therapeutics, Inc. (NASDAQ:PSTV) Receives Average Rating of "Moderate Buy" from Analysts - MarketBeat
How Plus Therapeutics Inc. stock responds to policy changes2025 Market Overview & Safe Entry Momentum Tips - ulpravda.ru
Is Plus Therapeutics Inc. (XMP0) stock a top hedge fund pick2025 Momentum Check & Real-Time Stock Price Movement Reports - Улправда
Can Plus Therapeutics Inc. (XMP0) stock ride next bull market cycleQuarterly Trade Summary & Weekly Breakout Stock Alerts - Улправда
Plus Therapeutics Inc (PSTV) 財務データ
収益
当期純利益
現金流量
EPS
Plus Therapeutics Inc (PSTV) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| Sims Andrew John Hugh MacIntyr | Chief Financial Officer |
Jan 01 '26 |
Option Exercise |
0.00 |
38,323 |
0 |
106,461 |
| Sims Andrew John Hugh MacIntyr | Chief Financial Officer |
Nov 04 '25 |
Buy |
0.51 |
20,000 |
10,200 |
68,138 |
| HEDRICK MARC H | Chief Executive Officer |
Oct 01 '25 |
Option Exercise |
0.00 |
159,681 |
0 |
180,106 |
| Sims Andrew John Hugh MacIntyr | Chief Financial Officer |
Oct 01 '25 |
Option Exercise |
0.00 |
38,323 |
0 |
48,138 |
| Lenk Robert P | Director |
Aug 22 '25 |
Buy |
0.49 |
110,000 |
53,779 |
139,327 |
4.73%
0.92%
大文字化:
|
ボリューム (24 時間):